TD Asset Management
GLUE icon

TD Asset Management’s Monte Rosa Therapeutics GLUE Stock Holding History

TD Asset Management’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.92M Sell
285,936
-1,042
-0.4% -$19.7K 0.01% 739
2026
Q1 		$4.72M Buy
286,978
+73,514
+34% +$1.41M ﹤0.01% 804
2025
Q4 		$3.35M Buy
213,464
+41,386
+24% +$558K ﹤0.01% 872
2025
Q3 		$1.28M Hold
172,078
– – ﹤0.01% 1046
2025
Q2 		$776K Hold
172,078
– – ﹤0.01% 1092
2025
Q1 		$798K Sell
172,078
-48,018
-22% -$294K ﹤0.01% 1099
2024
Q4 		$1.53M Buy
220,096
+26,400
+14% +$198K ﹤0.01% 1062
2024
Q3 		$1M Hold
193,696
– – ﹤0.01% 1184
2024
Q2 		$724K Buy
193,696
+528
+0.3% +$2.69K ﹤0.01% 1216
2024
Q1 		$1.36M Hold
193,168
– – ﹤0.01% 1116
2023
Q4 		$1.09M Hold
193,168
– – ﹤0.01% 1167
2023
Q3 		$925K Buy
193,168
+76,550
+66% +$493K ﹤0.01% 1163
2023
Q2 		$799K Sell
116,618
-24,236
-17% -$157K ﹤0.01% 1173
2023
Q1 		$1.1M Hold
140,854
– – ﹤0.01% 1112
2022
Q4 		$1.07M Hold
140,854
– – ﹤0.01% 1127
2022
Q3 		$1.1M Hold
140,854
– – ﹤0.01% 1161
2022
Q2 		$1.36M Hold
140,854
– – ﹤0.01% 1120
2022
Q1 		$1.98M Buy
140,854
+8,678
+7% +$120K ﹤0.01% 1089
2021
Q4 		$2.7M Buy
132,176
+93,412
+241% +$1.96M ﹤0.01% 1059
2021
Q3 		$864K Hold
38,764
– – ﹤0.01% 1286
2021
Q2 		$950K Buy
+38,764
New +$790K ﹤0.01% 1276

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TD Asset Management's GLUE Position: Q2 2026 in Review

TD Asset Management reduced its Monte Rosa Therapeutics (GLUE) stake by 0.36% in Q2 2026, selling an estimated $19.7K and leaving 285,936 shares worth $6.92M. The position accounts for 0.01% of the portfolio, ranked #739.

TD Asset Management first reported a position in GLUE in Q2 2021 and has held it in 21 quarters since. 193 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • TD Asset Management held 285,936 shares of Monte Rosa Therapeutics worth $6.92M as of Q2 2026.
  • TD Asset Management sold 1,042 Monte Rosa Therapeutics shares in Q2 2026, an estimated $19.7K.
  • Monte Rosa Therapeutics made up 0.01% of TD Asset Management's portfolio in Q2 2026, its #739 holding.
  • TD Asset Management first reported a position in Monte Rosa Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • 193 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.